BioBusiness

A closer look at elastomer changeout times provides one example of using industry knowledge to improve operations and cost.

The authors discuss the technology and guidance required to achieve good KM in a biopharmaceutical company.

Recovery audits and other best practices in procurement can improve the bottom line.

BioPharm talks with Tarja Mottram, CEO of Action for Results, about key business considerations when starting out.

Collaboration can begin with a conversation.

The confluence of science, technology, and regulation will provide our industry with the guidance to move forward.

Representatives from leading CROs weigh in on key challenges tied to the biopharmaceutical R&D, including issues regarding bioequivalence, platform technologies, process analytics, and more.

An architectural wonder teaches the biopharmaceutical industry a valuable lesson in project management.

Because of the complexity of the manufacturing processes for biologics, transfer of these processes to a contract manufacturer presents challenges.

Social media use raises questions about applying old standards to new information technology.

Key business considerations when developing biosimilar products virtually.

Has the long-awaited guidance answered all of the industry's questions?

This month, we rewind to an article titled "Demystifying the New Biology."

Key technical considerations when developing a clinical project in the biotech world.

New educational programs are key to the industry's future and to safe, available drugs.

Industry announces plans for year ahead at annual JPMorgan Global Healthcare Conference.

Introducing a new way to think about sharing information in a patent-driven industry.

The benefits of harmonization may be on industry's wish list, but buying into change is another story.

Government plans require investment, partnership, and industry collaboration.

Greater emphasis on focus and efficiency for companies as market demands value in 2012.

Political leaders need to consider the impact of the biopharmaceutical industry on the economy.

With the rise in therapeutics comes more complex partnerships.

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

Inside the National Institutes of Health

Market considerations and new technologies must be recognized to achieve the full benefits of manufacturing prefilled syringes.